Lexaria Bioscience Corp. LEXX Archives - Page 31 of 39

TuesdayFeb 08, 2022 12:33 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Summarizes 2021 Milestones, Outlines 2022 Plans and Expectations, in Annual Letter to Shareholders

In 2021, Lexaria conducted several main studies evaluating DehydraTECH-processed CBD and nicotine The company has big plans for 2022, a year it expects to undertake three ground-breaking studies Lexaria hopes these three major studies will generate sufficient data to support either regulated IND-type applications or to stimulate corporate partnerships The company is eying larger national and international applications for DehydraTECH with the aim of generating revenue through licensing fees and royalties For Lexaria Bioscience (NASDAQ: LEXX), a drug delivery company whose patented DehydraTECH(TM) technology has proven effective in improving bioavailability, speed of onset, and efficiency of orally-delivered fat-soluble active molecules…

WednesdayFeb 02, 2022 2:14 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Significant Findings from Sildenafil Animal Study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has reported positive findings in its recent animal study. The study was designed to evaluate LEXX’s proprietary DehydraTECH(TM) processing of the phosphodiesterase inhibitor ("PDE5 inhibitor") sildenafil for potential use in the management of erectile dysfunction. According to the company, the DehydraTECHsildenafil delivered 74% more drug at four minutes than the concentration-matched, generic control formulation with faster and higher overall delivery of sildenafil into the bloodstream evidenced over the course of the study. The most recognizable sildenafil product available currently is Viagra(R), but some users find it slow to act. Lexaria hopes…

MondayJan 31, 2022 12:34 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Offers a Glimpse into Company’s Unique Technology and Operations on EDGE Podcast

Chris Bunka, the Chairman and CEO of Lexaria, featured on the EDGE podcast hosted by Brandon C. White He provided insight into his background, professional philosophies, and Lexaria’s operations, with a focus on the company’s patented DehydraTECH(TM) technology Mr. Bunka also advised small companies and entrepreneurs, citing the importance of understanding the competitive environment Chris Bunka, the Chairman and Chief Executive Officer (“CEO”) of Lexaria Bioscience (NASDAQ: LEXX), was recently featured on episode 234 of the EDGE Podcast. Hosted by Brandon C. White, an Angel Investor and Entrepreneur, Mr. Bunka shared insights into his professional journey while also sharing what…

ThursdayJan 27, 2022 12:30 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Issues Annual Letter from CEO, Stakeholder Update

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today provided an annual letter from CEO Chris Bunka and a thorough strategic update to all stakeholders. In the update, Bunka described Lexaria’s key area of focus to improve the company’s understanding of the capabilities of its ground-breaking DehydraTECH(TM) drug-delivery technology to enhance its abilities to commercialize and profit from this technology platform. “DehydraTECH is not an EVOLUTION of existing technology – it is a REVOLUTIONARY new drug delivery platform,” Bunka explains in the letter. “Expecting entire industries to change overnight to adopt a revolutionary new process is…

ThursdayJan 27, 2022 11:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Emphasizes Oral Cannabinoid Delivery Benefits Following SARS-CoV-2 Study

The study is available for public viewing and is entitled “Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants” (https://ibn.fm/w6zLQ) Dr. Richard van Breeman, who headed the independent study, explained that smoking and vaping cannabinoids are ineffective against preventing SARS-CoV-2, whereas oral delivery methods are effective Lexaria has been studying and researching the oral delivery of compounds using its patented DehydraTECH(TM) technology, which enhances bioavailability and absorption, requiring less heat than smoking or vaping and leaving the cannabinoid compounds undamaged Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, commented on an independent January 10 study headed…

ThursdayJan 20, 2022 1:03 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Featured in EDGE Podcast Interview

Lexaria Bioscience (NASDAQ: LEXX) CEO and chair Chris Bunka is the guest on a recent episode of the EDGE podcast. Hosted by entrepreneur and angel investor Brandon C. White, the EDGE is a podcast series focused on providing a playbook for business owners that takes a look at the inner game of building a successful business and giving listeners the edge to become smarter, healthier and richer. Lexaria Bioscience is a global innovator in drug-delivery platforms. During the interview, Bunka shared his background and the journey that led him to Lexaria. He also talked about Lexaria’s business model and the…

ThursdayJan 20, 2022 12:59 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Marks Great Start to its 2022 R&D Programs Following Independent Review Board Approval

Lexaria received independent review board approval for its HYPER-H21-4 human clinical study for hypertension treatment The stage is also set for other R&D programs for the 2022 calendar year, including HOR-A22-1, DEM-A22-1, RHEUM-A22-1 and DIAB-A22-1 All of these 2022 R&D programs are fully funded, with Lexaria having raised approximately $15 million over the 2021 calendar year Lexaria believes that these programs will build significant value for its stakeholders and pursue policies for substantial improvements to human health In late 2021, Lexaria Bioscience (NASDAQ: LEXX) announced several new and ongoing R&D programs for its patented DehydraTECH(TM) technology. While making the announcement,…

TuesdayJan 18, 2022 4:08 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Provides Comments Regarding Study Examining Cannabinoids and SARS-CoV-2

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has commented on a recent study that indicated that cannabinoids have the potential to prevent as well as treat infection by SARS-CoV-2. The comments came from lead research scientist Dr. Richard van Breeman, who granted an interview with vice.com discussing the independent study. In his comments, Breemen observed that smoking or vaping of cannabis was likely not effective, but oral delivery was, causing Breeman to recommend oral administration of cannabis compounds. Lexaria is keenly interested in the study because the company is actively engaged in research with its exclusive DehydraTECH(TM)-powered cannabinoid formulations,…

FridayJan 14, 2022 12:47 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Leveraging DehydraTECH(TM) to Deliver More Effective Oral Medicine

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator of drug delivery platforms, is increasing the effectiveness of orally administered drugs. With oral absorption being the most convenient and widely used route for taking medications, decades of research have advanced the understanding of critical factors controlling oral bioavailability. Scientists are now better understanding the physiological function and formulation functionality that has been used in designing improved and more desirable oral medicine delivery through extensive research. Lexaria is accomplishing this through its patented DehydraTECH(TM) technology. “DehydraTECH improves the way that active pharmaceutical ingredients (‘APIs’) make their way into the bloodstream. This is…

FridayJan 14, 2022 9:53 am

After a Successful 2021, Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks Off 2022 With New Media Strategy, Plans for Clinical Study Advancements

Lexaria has multiple studies planned that will commence early in 2022 DehydraTECH increases Lexaria’s ability to leverage multiple markets, including the growing CBD sector, which is expected to meet and exceed $108 billion in revenue by 2027 DehydraTECH can increase the efficacy of the drugs being administered, offering faster absorption and lowering the delivery time In a strategic move to start off 2022, Lexaria Bioscience (NASDAQ: LEXX), a global innovator of drug delivery platforms, has announced that it has signed an advertising and media contract with financial technology company SRAX (NASDAQ: SRAX). The contract will facilitate media buys and digital…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LEXX